Drug Trial Radar · NCT03456700
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Mar 30, 2018
Primary completion
Jul 31, 2019
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.
Conditions
- Ovarian Serous Tumor
- Recurrent Ovarian Carcinoma
Interventions
AuranofinDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
SirolimusDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Confirmed Tumor Response (Partial Response [PR] or Complete Response [CR] at Least 4 Weeks Apart)Time frame: 1 year 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.